Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROMA LA-OPSCC-2: MET-4 with Chemoradiotherapy in Oropharyngeal Squamous Cell Carcinoma
NCT03838601Completed
- Sponsor
- University Health Network
- Start
- Jul 2019
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial of MET-4 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by University Health Network. Primary endpoints: Toxicity defined by CTCAE v.5.0 at 1 year and Relative abundance of MET-4 associated bacterial strains in stool samples at 2 months. Started Jul 2019; status: completed.
02
Drugs
MET-4
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03838601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838601.